Characterizing a tumor’s specific redox signature—through genetic sequencing of KEAP1/NRF2, immunohistochemistry for antioxidant proteins, or advanced imaging probes that can non-invasively map redox states—is essential for selecting the right patients for the right therapy [211,212,213]. Here, NFE2L2 is linked to neoplasm.